Diuretic usage for protection against end‐organ damage in liver cirrhosis and heart failure
- 11 May 2016
- journal article
- review article
- Published by Wiley in Hepatology Research
- Vol. 47 (1) , 11-22
Abstract
Volume overload is common in liver cirrhosis, heart failure, and chronic kidney disease, being an independent risk factor for mortality. Loop diuretics have been widely used for treating volume overload in these patients. However, there is a tendency to increase the dose of loop diuretics partly because of diuresis resistance. Neurohormonal factors are also enhanced in these patients, which play a role in volume overload and organ ischemia. Loop diuretics cannot improve neurohormonal factors and could result in end‐organ damage. The water diuretic tolvaptan has been approved for use for volume overload in heart failure and liver cirrhosis. Despite causing similar increases in urine volume, its characteristics differ from those of loop diuretics. Renal blood flow is maintained with tolvaptan but decreased with furosemide in heart failure patients. Neurohormonal factors and blood pressure are not markedly altered by tolvaptan administration. It is expected that these mechanisms of tolvaptan can protect against worsening renal function by volume overload diseases compared with loop diuretics. It has also been reported that some patients do not respond well to tolvaptan. Loop diuretics and tolvaptan share the same mechanism with regard to decreasing renal interstitial osmolality, which plays a fundamental role in water diuresis. Thus, a high dose of loop diuretics could result in resistance to tolvaptan, so tolvaptan should be administered before increasing the loop diuretic dose. Therefore, volume control without enhancing end‐organ damage can be achieved by adding tolvaptan to a tolerable dose of Na‐sparing diuretics.Keywords
This publication has 49 references indexed in Scilit:
- Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedemaJournal of International Medical Research, 2013
- Biophysical Insight into Furosemide Binding to Human Serum Albumin: A Study To Unveil Its Impaired Albumin Binding in UremiaThe Journal of Physical Chemistry B, 2013
- Novel Criteria of Urine Osmolality Effectively Predict Response to Tolvaptan in Decompensated Heart Failure PatientsCirculation Journal, 2013
- Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney DiseaseNew England Journal of Medicine, 2012
- Phase III Clinical Pharmacology Study of TolvaptanCardiovascular Drugs and Therapy, 2011
- Efficacy and Safety of Tolvaptan in Heart Failure Patients with Volume Overload Despite the Standard Treatment with Conventional Diuretics: A Phase III, Randomized, Double-blind, Placebo-controlled Study (QUEST Study)Cardiovascular Drugs and Therapy, 2011
- Urinary Concentration and Dilution in the Aging KidneySeminars in Nephrology, 2009
- High Perfusion Pressure Accelerates Renal Injury in Salt-Sensitive HypertensionJournal of the American Society of Nephrology, 2008
- Arginine Vasopressin–Mediated Stimulation of Nitric Oxide Within the Rat Renal MedullaHypertension, 1998
- Underfilling versus Overflow in Hepatic AscitesNew England Journal of Medicine, 1982